Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

Allergan

Status and phase: Completed; Phase 4

Conditions: Glaucoma; Ocular Hypertension

Treatments: Drug: latanoprost 0.005% eye drops and brimonidine 0.1% eye drops; Drug: latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops

Study type: Interventional

Funder types: Industry

Identifiers

NCT00440141

MA-AP01

Details and patient eligibility

About

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0.005%

Enrollment: 40 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Glaucoma or ocular hypertension in both eyes
• Currently being treated with latanoprost 0.005% QD
• IOP greater than or equal to 18mm Hg on latanoprost 0.005%
• Best-corrected VA of 20/200 or better in each eye
• Visual field within 6 months of study entry

Exclusion criteria

• Secondary glaucoma
• Active intraocular inflammation or macular edema
• Intraocular surgery or laser surgery within the past 3 months

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

40 participants in 2 patient groups

1

Experimental group

Treatment:

Drug: latanoprost 0.005% eye drops and brimonidine 0.1% eye drops

2

Active Comparator group

Treatment:

Drug: latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops